© 2023 Vir Biotechnology, Inc. 1 Corporate Overview May 4, 2023 NIR LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the "Company" or "Vir"), the Company's strategy and plans; capital allocation; future financial and operating results and its expectations related ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 81-2730369 | | --- | --- | | (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact Name of Registrant as Specified in its Charter) Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. Delaware 81-2730369 (State or Other Jurisdiction o ...

Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial Edward Gane1, Alina Jucov2, Marta Dobryanska3, Ki Tae Yoon4, Tien-Huey Lim5, Andre Arizpe6, Daniel Cloutier6, Ling Shen6, Sneha V. Gupta6, Audrey H. Lau6, Carey Hwang6, Young-Suk Lim7 1Faculty of Medicine, University of Auckland, Auckland, New Zealand; 2Ar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-2730369 (State or Other Juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-2730369 (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) WASHINGTON, DC 20549 FORM 10-Q Delaware 81-2730369 (State or Other Jurisdic ...

NIR WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus A World Without Infectious Disease Corporate Overview February 24, 2022 VIR BIOTECHNOLOGY, INC. LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the nearterm financial performance (including near-term collaboration revenue related to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its ...

NIR WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus A World Without Infectious Disease J P M O R G A N H E A L T H C A R E C O N F E R E N C E J a n u a r y 1 1 , 2 0 2 2 V I R B I O T E C H N O L O G Y , I N C . L E G A L D I S C L A I M E R Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the nearter ...